Pharma startups like Pharnext are deploying machine learning to search for new therapeutic uses for “off patent” medications.
In the elegant quiet of the café at the Church of Sweden, a narrow Gothic-style building in Midtown Manhattan, Daniel Cohen is taking a break from explaining genetics. He moves toward the creaky piano positioned near the front door, sits down, and plays a flowing, flawless rendition of “Over the Rainbow.”
If human biology is the scientific equivalent of a complicated score, Cohen has learned how to navigate it like a virtuoso. Cohen was the driving force behind Généthon, the French laboratory that in December 1993 produced the first-ever “map” of the human genome. He essentially introduced Big Data and automation to the study of genomics, as he and his team demonstrated for the first time that it was possible to use super-fast computing to speed up the processing of DNA samples.
Scientists worldwide have built on Cohen’s insights, and Cohen himself, an MD with a Ph.D. in immunology, has gone on to success as a researcher and pharma executive. But a quarter-century later, genomics has yielded few of the kinds of paradigm-changing medical breakthroughs that many of its early innovators hoped for. Today, as chief executive and founder of Paris-based drug startup Pharnext, Cohen is striving to understand why that rainbow hasn’t led to a pot of gold.
“Any protein in the body has many different functions, not only one,” he says, returning from the piano to talk with me, “just as you are a person who has many functions in the population, not just one.” The phenomenon Cohen is describing is “pleiotropy,” the capacity of a single gene to have multiple, seemingly unrelated effects. It is one of the complexities of disease that has repeatedly frustrated medical researchers in their quest for therapies for the most stubborn illnesses.
Cohen not only appreciates pleiotropy’s significance: He believes that Pharnext and other drugmakers may soon exploit it—with a powerful boost from artificial intelligence. By embracing the body’s complexity, and by using A.I. to more methodically analyze and map the way the chain reactions of disease sweep through the body, he hopes to develop combinations of drugs tuned to attack a plethora of medical conditions.
Image Credit: Roberto Frankenberg
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News This Week
“The most crucial result of this work is the correlation between form and function in supercapacitor materials,” states first author Dina Ibrahim Abouelamaiem. She elaborates that “our research is driven by the need for [...]
“We’ll have nanobots that… connect our neocortex to a synthetic neocortex in the cloud. Our thinking will be a…. biological and non-biological hybrid.” Ray Kurzweil, TED 2014 UPDATE - June 18 2019 Since [...]
A new study by the Environmental Working Group reveals that: “Major food companies like General Mills continue to sell popular children’s breakfast cereals and other foods contaminated with troubling levels of glyphosate, the cancer-causing [...]
A nanotechnology treatment derived from bone marrow stem cells has reversed multiple sclerosis symptoms in mice and could eventually be used to help humans, according to a new study led by University of California, [...]
In a paper published this week in Nature ("Freestanding crystalline oxide perovskites down to the monolayer limit"), materials science researchers at the University of California, Irvine and other institutions unveil a new process for [...]
New research provides insight into the structure of silicon nanocrystals, a substance that promises to provide efficient lithium ion batteries that power your phone to medical imaging on the nanoscale. The research was conducted [...]
Several space missions, planned by both the European Space Agency and NASA, have their target set on Jupiter and its moons. The extraordinarily harsh radiation environments in the Jovian system will set some strict [...]
rance is clamping down on a common food additive that has been shown to be carcinogenic in animal studies. The ban of titanium dioxide, announced by the French government last month, follows a review [...]
Today’s societies critically depend on electronic systems. Past spectacular cyber-attacks have clearly demonstrated the vulnerability of existing systems and the need to prevent such attacks in the future. The majority of available cyber-defenses concentrate [...]
Researchers of the Nanoscience Center (NSC) at the University of Jyväskylä, Finland, and in the Xiamen University, China, have discovered how copper particles at the nanometre scale operate in modifying a carbon–oxygen bond when [...]
Cells in the body are wired like computer chips to direct signals that instruct how they function, research suggests (Nature Communications, “The cell-wide web coordinates cellular processes by directing site-specific Ca2+ flux across cytoplasmic [...]
We may be able to detect cancer soon by simply peeing on a stick. - Cancer is an aberrant function of a normal cell, where the regulators of that cell's dividing are broken [...]
Microcontaminants place a considerable burden on our water courses, but removing them from wastewater requires considerable technical resources. Now, ETH researchers have developed an approach that allows the efficient removal of these problematic [...]